All Tox In Focus volumes
Tox In Focus
|
Focused Clinical Reference
Vol. 27  ·  Antipsychotics  ·  July 2026
ANTIPSYCHOTICS
Adherence monitoring, the risperidone-paliperidone link, and the quetiapine false positive

Antipsychotic monitoring by LC-MS/MS confirms adherence to first- and second-generation agents used for schizophrenia, bipolar disorder, and as adjuncts in depression and anxiety. Two interpretation points stand out: risperidone's active metabolite hydroxyrisperidone is paliperidone (Invega), a marketed drug in its own right, and quetiapine is a well-known cause of methadone false positives on immunoassay.1

Why This Matters Now

Adherence to antipsychotics is often poor and hard to verify by history alone, and a specific LC-MS/MS result documents recent use between visits. It also resolves the quetiapine-driven methadone false positive that can otherwise appear on an immunoassay screen.3

⚠ A methadone immunoassay positive in a patient taking quetiapine may be a cross-reaction; confirm methadone and EDDP by LC-MS/MS. And a paliperidone result can reflect prescribed risperidone.
Clinical Presentation
ADVERSE EFFECTS
Sedation, orthostatic hypotension
Extrapyramidal symptoms, akathisia
Metabolic effects (weight, glucose, lipids)
QT prolongation (some agents)
Neuroleptic malignant syndrome (rare)
MONITORING CAUTIONS
Clozapine: agranulocytosis (ANC monitoring)
Abrupt stop: rebound or withdrawal dyskinesia
Tardive dyskinesia with long-term use
CYP interactions alter measured levels
Unexpected negative may signal non-adherence
Important: Risperidone's active metabolite hydroxyrisperidone is paliperidone (Invega), so a paliperidone result can reflect prescribed risperidone rather than separate use. Quetiapine can produce a methadone immunoassay false positive.
UDT Considerations

LC-MS/MS measures specific antipsychotics and key metabolites (e.g., norquetiapine, hydroxyrisperidone). Absence in a prescribed patient may reflect non-adherence, PRN use, a drug interaction, or altered CYP metabolism. When a methadone immunoassay is unexpectedly positive in a patient on quetiapine, confirm methadone and EDDP by LC-MS/MS to exclude cross-reactivity.3

Clinical Guidance
  • Order specific LC-MS/MS to document adherence; there is no antipsychotic immunoassay.1
  • Read a paliperidone result as possibly reflecting prescribed risperidone (its active metabolite).
  • Confirm methadone with LC-MS/MS when an immunoassay is positive in a quetiapine-treated patient.3
  • Interpret an unexpected negative as possible non-adherence, PRN use, or altered CYP metabolism.2
  • Account for CYP interactions and genetics that shift measured levels.2
Point-of-Care Testing Availability
Available strips
No point-of-care strip detects antipsychotics.
Clinical use
Quetiapine is a documented cause of methadone immunoassay false positives.
Limitations
LC-MS/MS confirms the specific antipsychotic and metabolite.
ANTIPSYCHOTICS  |  Clinical & Program Guidance
Tox In Focus Vol. 27  ·  July 2026  ·  Page 2 of 2
Interpreting the Test Result
▲  If Testing Is Positive

Confirms recent use. Detection indicates use within the estimated window; levels do not confirm dose or schedule.

Paliperidone may be risperidone. Hydroxyrisperidone (paliperidone) is risperidone's active metabolite; a positive can reflect prescribed risperidone.

Can explain a methadone screen. Quetiapine can cross-react on the methadone immunoassay; confirm by LC-MS/MS.3

Analytes and Estimated Urine Detection Windows
AntipsychoticUrine analyte(s)Estimated window
AripiprazoleAripiprazole (OPC-3373)Up to ~16 days
OlanzapineOlanzapine4-12 days
QuetiapineQuetiapine, norquetiapine1-2 days
RisperidoneRisperidone, hydroxyrisperidoneParent ~5 d; metabolite ~6 d
PaliperidoneHydroxyrisperidone~6 days
HaloperidolHaloperidol (+ metabolite)~5 days
ClozapineClozapine, N-desmethylclozapine2-3 days
LamotrigineLamotrigine5-7 days

Windows estimated from half-life (about 5x t-half); note that hydroxyrisperidone is paliperidone (Invega).

Key References
  1. Patteet L, Morrens M, Maudens KE, et al. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit. 2012;34(6):629-651.
  2. Murphy LE, Fonseka TM, Bousman CA, et al. Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Mol Psychiatry. 2021.
  3. Reisfield GM, Goldberger BA, Bertholf RL. 'False-positive' and 'false-negative' test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952.
DISCLAIMER: This document is intended for clinical reference and educational purposes only. It does not constitute medical, legal, or professional advice and should not replace independent clinical or programmatic judgment. Content reflects published data available at time of preparation. ToxiPharm LLC makes no warranties regarding completeness or applicability in all settings.  |   © 2026 ToxiPharm LLC  |  toxipharm.org
Back to Tox In Focus ToxiPharm home →